Pioneers in the Constellation
of Cannabis, Cancer, and Diagnostics.
Personalization of cannabinoid-based treatments is our main scope, addressing the rapidly growing yet unmet need of cancer patients who are prescribed with cannabis. The multifactorial benefits of cannabis create an arising need that may unravel a new attitude to cancer treatment and prevention.
The number of cancer patients, caregivers and doctors that are exposed to cannabis is growing rapidly as new countries i.e. Germany, Canada, Australia and others, join with the US and Canada and are adopting new regulations and introduce natural cannabis products to the health system.
Despite significant progress in cancer diagnostics and development of novel therapeutic regimens, successful treatment of advanced forms of cancer is still a challenge and may require personalized therapeutic approaches. Our licensed Israeli facility operates a unique research and development laboratory which combines high throughput screening (“HTS”) capabilities with the most advanced data tools. The HTS platform allows us to test many compounds on cancerous cell lines and tissues and measure the therapeutic effects of these compounds. Our advantage is in the specialized library which is composed of a collection of cannabis extracts and pure natural and synthetic cannabinoids.
STATE OF THE ART FULLY LICENSED RESEARCH FACILITY
DEFENSIVE APPROACH - YOU SHOULD KNOW THIS
Some Cannabinoid Compositions May Interfere With Chemotherapy Treatments.